EGFR and non-small cell lung carcinoma: First, we examined the effects of erlotinib and gefitinib on cell growth of various NSCLC cell lines harboring EGFRWT (H292, H322, A549, H460, and H23) or EGFR activating mutations (HCC827 and H3255) by colony formation assay (Fig. 2a).